Cuba can produce enough Interferon to treat Covid-19

 Cuba’s National Biopreparation Center (Biocen) now has the capacity to produce all the recombinant Interferon alpha 2b necessary to deal with Covid-19, according to its authorities.

The levels reach 50,000 bulbs daily in the liquid form of the compound; and of the lyophilized (powder that is reconstituted before being injected), 40,000 are achieved weekly, stated the entity’s production director, Gabriel Gonzalez.

Quoted by Granma newspaper, Gonzalez stressed that this center is the only one in the country with the license to produce both forms of Interferon, requested by more than 45 nations to deal with the pandemic caused by the SARS Cov-2 coronavirus.

By next April, he added, a new filling line will be validated that will make possible the production of 100,000 bulbs per day of the fluid version.

According to Gonzalez, the institution has a high responsibility with each product manufactured there, because they are injectable drugs that require a high hygienic and sterilization control.

Humberto Perez, head of the parenteral (injectable drug) production plants at Biocen, explained that the development of Interferon consists of several stages.

On the other hand, Perez highlighted the Biocen quality system, based on good pharmaceutical manufacturing practices, and acknowledged its work to guarantee export orders in the midst of the current global pandemic.

It is nothing new for us to work under pressure and against demand, tenders are won in several countries, and these terms include agreed quantities and time limits for delivery, he stressed.

Lab/ Taked from Prensa Latina

Impactos: 0

Deja una respuesta

Tu dirección de correo electrónico no será publicada.

19 − doce =